ABEO - Abeona Therapeutics Inc.
| Previous Close | 17.300 |
| Open | 17.200 |
| Bid | 17.050 x 100 |
| Ask | 19.950 x 100 |
| Day's Range | 16.350 - 17.230 |
| 52 Week Range | 4.550 - 22.750 |
| Volume | 150,464 |
| Avg. Volume | 1,252,112 |
| Market Cap | 801.11M |
| Beta | 2.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.656 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.72 |
- ACCESSWIRE•2 days ago
Wired News – European Medicines Agency Granted Orphan Drug Designation for Abeona’s ABO-202 Gene Therapy Program in Batten Disease
LONDON, UK / ACCESSWIRE / April 24, 2018 / Active-Investors.com has just released a free research report on Abeona Therapeutics Inc. (NASDAQ: ABEO). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ABEO as the Company's latest news hit the wire. On April 20, 2018, the Company announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeona`s gene therapy program ABO-202 for the treatment of subjects with neuronal ceroid lipofuscinosis, also known as Batten Disease, a rare, fatal, autosomal recessive (inherited) disorder of the nervous system.
- GlobeNewswire•3 days ago
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation. NEW YORK and CLEVELAND, April 23, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical ...
- GlobeNewswire•6 days ago
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies ...
- GlobeNewswire•6 days ago
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
NEW YORK and CLEVELAND, April 20, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
- Simply Wall St.•13 days ago
When Will Abeona Therapeutics Inc (NASDAQ:ABEO) Breakeven?
Abeona Therapeutics Inc’s (NASDAQ:ABEO): Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. On 31 December 2017, theRead More...
- Zacks•16 days ago
Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump
Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
- ACCESSWIRE•16 days ago
Today’s Research Reports on Trending Tickers: Abeona Therapeutics and Spark Therapeutics
NEW YORK, NY / ACCESSWIRE / April 10, 2018 / U.S. markets rallied in early trading Monday on the strength of technology stocks and the easing of trade relations between the U.S. and China. However, most ...
- GlobeNewswire•20 days ago
Report: Exploring Fundamental Drivers Behind Haverty Furniture Companies, Scholastic, Dover, MYR Group, Abeona Therapeutics, and U.S. Global Investors — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, April 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•24 days ago
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare diseases Tim Miller, Ph.D. continues as president and assumes chief ...
- GlobeNewswire•24 days ago
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare diseases Tim Miller, Ph.D. continues as president and assumes chief ...
- Investopedia•24 days ago
7 Stocks for the Biotech Takeover Wave
Biotech M&A activity took a bit of a breather in 2017, but expect a new wave of deals in 2018.
- Thomson Reuters StreetEvents•last month
Edited Transcript of ABEO earnings conference call or presentation 27-Mar-18 2:00pm GMT
Q4 2017 Abeona Therapeutics Inc Earnings Call
- ACCESSWIRE•last month
Abeona Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 27, 2018 / Abeona Therapeutics, Inc. (NASDAQ: ABEO ) will be discussing their earnings results in their Q1 Earnings Call to be held on March 27, 2018, at 10:00 AM Eastern ...
- TheStreet.com•last month
15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies
'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.
- GlobeNewswire•last month
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
Investor Conference Call on Tuesday, March 27th at 10:00 am ET NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical ...
- GlobeNewswire•last month
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
NEW YORK and CLEVELAND, March 16, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
- GlobeNewswire•last month
Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
NEW YORK and CLEVELAND, March 15, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
- GlobeNewswire•2 months ago
New Research Coverage Highlights Western Alliance, Matson, Vail Resorts, Abeona Therapeutics, Under Armour, and AGNC Investment — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Feb. 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Western ...
- GlobeNewswire•2 months ago
Abeona Therapeutics Announces Upcoming Conference Participation
NEW YORK and CLEVELAND, Feb. 21, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
- GlobeNewswire•2 months ago
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease
NEW YORK and CLEVELAND, Feb. 12, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
- GlobeNewswire•3 months ago
Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
ABO-102 results presented at WORLDSymposium for Lysosomal Diseases show significant time- and dose-dependent reduction of underlying disease pathology, including decreased CSF and urine GAGs and diminished ...
- Motley Fool•3 months ago
Why Abeona Therapeutics Jumped 14% on Wednesday
Positive clinical trial data from a single patient sends shares soaring.
- TheStreet.com•3 months ago
Traders Need to Adapt to a New Reality
The volatility trade that propped up markets is no longer available.
- GlobeNewswire•3 months ago
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
First-in-man AAV9-based gene therapy delivered by single intravenous injection targeting central nervous system and peripheral manifestations of MPS IIIB. ABO-101 is well tolerated and demonstrates early ...
- GlobeNewswire•3 months ago
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
First-in-man AAV9-based gene therapy delivered by single intravenous injection targeting central nervous system and peripheral manifestations of MPS IIIB. ABO-101 is well tolerated and demonstrates early ...
